Adult Malignant Glioma Therapeutics Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The adult malignant glioma therapeutics market size has grown rapidly in recent years. It will grow from $2.25 billion in 2024 to $2.48 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increased incidence rates, patient advocacy initiatives, personalized medicine approaches.

The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.55 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to immunotherapy advancements, targeted therapies, biomarker discoveries, liquid biopsy applications, expanded access programs. Major trends in the forecast period include patient-centric drug development, fast-track and breakthrough designation, advances in drug delivery systems, collaborative research initiative, integration of artificial intelligence.

The upward trajectory in brain tumor cases is anticipated to be a significant driver in propelling the growth of the adult malignant glioma therapeutics market. Brain tumors represent anomalous masses of tissue characterized by the abnormal proliferation and unchecked growth of cells, circumventing the usual regulatory mechanisms. Adult malignant glioma, a specific type of brain tumor, comprises cells exhibiting abnormal and uncontrolled growth patterns. Treatment for adult malignant glioma typically involves a combination of surgical procedures, radiation therapy, and chemotherapy. Illustrating this trend, as per the American Cancer Society's January 2023 report, the number of cases related to brain and nervous system cancers escalated to 24,810 in 2023, demonstrating a notable 3.85% increase from 23,890 recorded in 2020. Thus, the mounting instances of brain tumors serve as a driving force behind the expansion of the adult malignant glioma therapeutics market.

The infusion of government funding dedicated to brain cancer research is poised to significantly propel the growth trajectory of the adult malignant glioma therapeutics market moving forward. Government funding entails financial support disbursed by governmental bodies at various levels - federal, state, or local - towards initiatives, programs, projects, organizations, or individuals. The allocation of government funds for brain cancer research holds substantial promise for advancing adult malignant glioma therapeutics. This funding can significantly aid in the development of innovative treatments, tailored drug design, focusing on pyrimidine synthesis, and expediting orphan drug approvals. For example, in June 2023, the Australian Department of Health and Aged Care initiated the Australian Brain Cancer Mission, committing a fund of $136.66 million specifically aimed at supporting brain cancer research endeavors. The primary objective of this initiative is to double survival rates and enhance the overall quality of life for brain cancer patients, including those with anaplastic astrocytoma. Consequently, government funding geared towards brain cancer research stands as a pivotal driver propelling the adult malignant glioma therapeutics market.

Leading companies within the adult malignant glioma therapeutics market are actively engaged in the development of innovative products, notably small molecule targeted degraders, aimed at providing enhanced and dependable customer service. Small-molecule targeted degraders represent a class of drugs employing small molecules to induce the degradation of specific proteins by targeting both the protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a precision oncology company based in Sweden, attained orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17 designed to treat glioblastoma (GBM). BEA-17 functions as a small-molecule targeted degrader targeting the epigenetic enzyme LSD1 and its co-factor CoREST, implicated in the pathogenesis of various cancers, including GBM. The drug works by degrading LSD1 and CoREST, leading to the reactivation of tumor suppressor genes and inhibiting the growth of cancer cells. This innovative approach holds promise in advancing treatment options within the adult malignant glioma therapeutics market.

In May 2024, Novartis, a Switzerland-based pharmaceutical company, acquired Mariana Oncology for $1 billion. This acquisition is intended to enhance Novartis's pipeline in radioligand therapies (RLTs) for various cancers, including potential applications for solid tumors like gliomas. Mariana Oncology, a US-based preclinical-stage biotechnology firm, focuses on developing therapeutics for gliomas.

Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan PLC, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

North America was the largest region in the adult malignant glioma therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adult malignant glioma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adult malignant glioma therapeutics market consists of revenues earned by entities by providing services such as resection, subtotal resection, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The adult malignant glioma therapeutics market consists of sales of temozolomide, bevacizumab, carmustine, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The field of adult malignant glioma therapeutics focuses on treating brain tumors that originate in the glial cells of the brain or spinal cord, particularly in adults. This encompasses various treatment options designed to enhance the quality of life and extend the survival of individuals affected by malignant gliomas.

The primary subtypes of adult malignant glioma therapeutics include glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme (GBM), known for its aggressive nature, involves rapid tumor growth and the infiltration of neighboring brain tissue, typically without distant organ metastasis. Therapeutic interventions in this domain encompass chemotherapy, targeted therapy, radiotherapy, and other modalities. These treatments are administered in various healthcare settings, including hospitals, specialty clinics, and cancer and radiation therapy centers.

The adult malignant glioma therapeutics market research report is one of a series of new reports that provides adult malignant glioma therapeutics market statistics, including adult malignant glioma therapeutics industry global market size, regional shares, competitors with a adult malignant glioma therapeutics market share, detailed adult malignant glioma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the adult malignant glioma therapeutics industry. This adult malignant glioma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.